Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + KN046 + AG chemotherapy for unresectable advanced pancreatic cancer
ChiCTR2300071717Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib in pancreatic adenocarcinoma (PDAC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Objective response rate (RECIST 1.1) and Predictive biomarkers. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
surufatinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2300071717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071717.